Atea Pharmaceuticals (United States)

Recent papers from Atea Pharmaceuticals (United States)

1. Efficacy and safety of an 8-week bemnifosbuvir and ruzasvir regimen in chronic hepatitis C: Results from a Phase 2 studyHepatology · 2026
2. Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus InfectionClinical Pharmacology & Therapeutics · 2026
3. Consecutive catalytic steps of viral RNA polymerase and exonuclease suggest a way to overcome intrinsic nucleotide analogue resistanceProceedings of the National Academy of Sciences · 2026
4. Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of ActionClinical Pharmacology & Therapeutics · 2026
5. In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug-Metabolizing Enzymes.2026
6. P-1171. Assessment of the Fosfomycin 200 µg Disk Diffusion against Resistant Enterobacterales: Data from the Intravenous Fosfomycin (IV-FOS) Clinical Trial Program for Complicated Urinary Tract InfectionOpen Forum Infectious Diseases · 2026
7. P-1170. Impact of Increased Severity of Illness on Outcomes in Complicated Urinary Tract Infections (cUTI) from ZEUS, a Randomized Controlled Trial (RCT) Evaluating IV Fosfomycin (IV-FOS)Open Forum Infectious Diseases · 2026
8. P-1172. Characterization of Clinical Pathogens and Microbiological Outcomes for Patients Treated with IV Fosfomycin (IV-FOS) in the ZEUS Phase 2/3 Complicated Urinary Tract Infection, including Acute Pyelonephritis (cUTI/AP) TrialOpen Forum Infectious Diseases · 2026
9. In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug TransportersThe Journal of Clinical Pharmacology · 2025
10. Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy ParticipantsClinical Pharmacology in Drug Development · 2025
11. Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivoAntiviral Research · 2025
12. The activation cascade of the broad-spectrum antiviral bemnifosbuvir characterized at atomic resolutionPLoS Biology · 2024
13. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19Journal of Antimicrobial Chemotherapy · 2024
14. First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virusAntimicrobial Agents and Chemotherapy · 2024
15. The activation chain of the broad-spectrum antiviral bemnifosbuvir at atomic resolution2024
16. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-192024
17. First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus2024
18. Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymeraseExpert Opinion on Investigational Drugs · 2024
19. An exonuclease-resistant chain-terminating nucleotide analogue targeting the SARS-CoV-2 replicase complexNucleic Acids Research · 2023
20. Oral Bemnifosbuvir (AT-527) Vs Placebo in Patients With mild-to-moderate COVID-19 in an Outpatient Setting (MORNINGSKY)Future Virology · 2023